Michael Barbella, Managing Editor12.09.23
Acquisitions and product approvals were highly endorsed this past week on ODT's website.
Topping pageviews was OrthoPediatrics Corp.'s launch of its new division for non-surgical intervention for pediatric orthopedics. The OrthoPediatrics Specialty Bracing division (OPSB) will serve as a flagship house of brands and innovative products that expand the company’s total addressable market by roughly $600 million. OrthoPediatrics first entered the non-operative space through the acquisition of MD Orthopaedics Inc. (MDO) in 2022 and its bracing product lines and the patented Mitchell Ponseti Ankle-Foot Orthosis (AFO) system for clubfoot treatment.
Exactech and OSSIO drove traffic with their respective FDA authorizations. Exactech subsidiary BlueOrtho gained FDA 510(k) clearance for the ExactechGPS Ankle, which reportedly is the world’s first surgical navigation system for total ankle arthroplasty.
GPS Ankle connects the preoperative plan with real-time intraoperative instrument guidance, then confirms that resections meet the surgical plan. The system’s active tracker tech and compact, touchscreen tablet in the sterile field offers surgeons dynamic, intraoperative feedback throughout their cases.
OSSIO contributed to OTD's pageview count with the FDA clearance of its OSSIOfiber bio-integrative fixation technology for use in orthopedic surgery for children needing bone fractures fixed, osteotomies, or fusions. OSSIOfiber compression screws and trimmable fixation nails can now be used in children ages 2 to 21 in standard clinical practice.
Nevro and HOPCo, meanwhile, garnered attention for their acquisitions. Nevro bought sacroiliac joint fusion developer Vyrsa Technologies for $40 million at closing and up to $35 million additional cash or stock, tied to achievement of certain development and sales milestones. HOPCo, conversely, purchased MyACTome, a validated smartphone-based fall risk and frailty assessment platform.
Topping pageviews was OrthoPediatrics Corp.'s launch of its new division for non-surgical intervention for pediatric orthopedics. The OrthoPediatrics Specialty Bracing division (OPSB) will serve as a flagship house of brands and innovative products that expand the company’s total addressable market by roughly $600 million. OrthoPediatrics first entered the non-operative space through the acquisition of MD Orthopaedics Inc. (MDO) in 2022 and its bracing product lines and the patented Mitchell Ponseti Ankle-Foot Orthosis (AFO) system for clubfoot treatment.
Exactech and OSSIO drove traffic with their respective FDA authorizations. Exactech subsidiary BlueOrtho gained FDA 510(k) clearance for the ExactechGPS Ankle, which reportedly is the world’s first surgical navigation system for total ankle arthroplasty.
GPS Ankle connects the preoperative plan with real-time intraoperative instrument guidance, then confirms that resections meet the surgical plan. The system’s active tracker tech and compact, touchscreen tablet in the sterile field offers surgeons dynamic, intraoperative feedback throughout their cases.
OSSIO contributed to OTD's pageview count with the FDA clearance of its OSSIOfiber bio-integrative fixation technology for use in orthopedic surgery for children needing bone fractures fixed, osteotomies, or fusions. OSSIOfiber compression screws and trimmable fixation nails can now be used in children ages 2 to 21 in standard clinical practice.
Nevro and HOPCo, meanwhile, garnered attention for their acquisitions. Nevro bought sacroiliac joint fusion developer Vyrsa Technologies for $40 million at closing and up to $35 million additional cash or stock, tied to achievement of certain development and sales milestones. HOPCo, conversely, purchased MyACTome, a validated smartphone-based fall risk and frailty assessment platform.